Phaseline

Companies › Axogen

Axogen: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 4; Other; next expected readout Dec 2030.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Avance Nerve Graft
Acellular nerve allograft scaffold derived from decellularized and sterilized extracellula
–Phase 4Peripheral Nerve InjuryDec 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07657182Avance Nerve GraftPhase 4Peripheral Nerve InjuryOtherDec 2030

From the company's SEC filings

Cash and short-term investments of $348m on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

CellTherX CUTISS Gameto Merz Aesthetics DBV Technologies

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.